Cystic Fibrosis: all 1,605 studies

Page 4 of 17. Open to participants first (196), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR MutationCompletedNCT03068312Phase 3Results posted
• Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR MutationCompletedNCT03061331Phase 2Results posted
• The Role of Oral Glutathione on Growth Parameters in Children With Cystic FibrosisCompletedNCT03020719Phase 2Results posted
• A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis ExacerbationsCompletedNCT03000348Phase 2Results posted
• BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF SubjectsCompletedNCT02976519Phase 1Results posted
• Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating MutationsTerminatedNCT02971839Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)CompletedNCT02953314Phase 3Results posted
• A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic FibrosisCompletedNCT02951195Phase 2Results posted
• A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic FibrosisCompletedNCT02951182Phase 2Results posted
• An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing MutationsCompletedNCT02934698Phase 3Results posted
• A Study of RPL554 in Patients With Cystic FibrosisCompletedNCT02919995Phase 2Results posted
• IV Colistin for Pulmonary Exacerbations: Improving Safety and EfficacyCompletedNCT02918409Phase 4Results posted
• A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCompletedNCT02875366Phase 4Results posted
• Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic FibrosisCompletedNCT02866721Phase 1Results posted
• EASY: Extended Access to Sollpura Over YearsCompletedNCT02823964Phase 4Results posted
• A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR MutationTerminatedNCT02823470Phase 4Results posted
• SPI-1005 for Prevention and Treatment of Tobramycin Induced OtotoxicityCompletedNCT02819856Phase 2Results posted
• Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCompletedNCT02797132Phase 3Results posted
• Standardized Treatment of Pulmonary Exacerbations IICompletedNCT02781610Phase 4Results posted
• Effect of Andecaliximab on FEV1 in Adults With Cystic FibrosisTerminatedNCT02759562Phase 2Results posted
• Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) StudyCompletedNCT02750501Not applicableResults posted
• A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating MutationTerminatedNCT02742519Phase 3Results posted
• SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic FibrosisCompletedNCT02734810Phase 3Results posted
• Aztreonam Aerosol to Treat Cystic Fibrosis Nasal DiseaseTerminatedNCT02730793Phase 2Results posted
• A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR MutationCompletedNCT02730208Phase 2Results posted
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR MutationCompletedNCT02725567Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR MutationCompletedNCT02709109Phase 2Results posted
• Inhaled Sodium Nitrite as an Antimicrobial for Cystic FibrosisTerminatedNCT02694393Phase 1/2Results posted
• To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose AdministrationCompletedNCT02679729Phase 1Results posted
• Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)CompletedNCT02677701Phase 4Results posted
• Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CFCompletedNCT02626182Phase 1/2Results posted
• Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic FibrosisCompletedNCT02613884Phase 2Results posted
• Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic AspectsCompletedNCT02603666Not applicableResults posted
• Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic FibrosisCompletedNCT02566044Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationCompletedNCT02565914Phase 3Results posted
• Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR MutationCompletedNCT02564354Phase 1Results posted
• Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With IvacaftorCompletedNCT02544451Phase 3Results posted
• Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis PatientsCompletedNCT02532764Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR MutationCompletedNCT02516410Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR MutationCompletedNCT02514473Phase 3Results posted
• A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT02508207Phase 2Results posted
• Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic FibrosisCompletedNCT02504827Phase 4Results posted
• The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis PatientsTerminatedNCT02496780Phase 2/3Results posted
• A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)CompletedNCT02477319Results posted
• Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisCompletedNCT02465450Phase 2Results posted
• Extension Study of Ataluren in Participants With Nonsense Mutation Cystic FibrosisTerminatedNCT02456103Phase 3Results posted
• Pharmacokinetics of Tedizolid Phosphate in Cystic FibrosisCompletedNCT02444234Phase 4Results posted
• EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) PatientsCompletedNCT02443688Phase 2Results posted
• Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CFCompletedNCT02423447Not applicableResults posted
• Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis PatientsCompletedNCT02421120Phase 4Results posted
• Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic FibrosisCompletedNCT02415959Phase 2Results posted
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to IvacaftorCompletedNCT02412111Phase 3Results posted
• A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) MutationCompletedNCT02392234Phase 3Results posted
• Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung DiseaseCompletedNCT02390219Phase 3Results posted
• Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic FibrosisCompletedNCT02372383Not applicableResults posted
• A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)CompletedNCT02354859Phase 2Results posted
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorCompletedNCT02347657Phase 3Results posted
• Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)TerminatedNCT02323100Phase 1/2Results posted
• (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?CompletedNCT02310789Not applicableResults posted
• Exploring Novel Interventions to Improve Adherence in Children With Cystic FibrosisCompletedNCT02301377Not applicableResults posted
• SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic FibrosisCompletedNCT02279498Phase 3Results posted
• Electro Flo 5000 and Vest TherapyCompletedNCT02277626Phase 4Results posted
• Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.AeruginosaTerminatedNCT02248922Phase 4Results posted
• Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia ComplexCompletedNCT02212587Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis PatientsTerminatedNCT02190604Phase 1/2Results posted
• Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis PatientsCompletedNCT02178540Phase 4Results posted
• Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis PatientsTerminatedNCT02170025Phase 2Results posted
• MRI for Non-Invasive Imaging in Neonates and ChildrenCompletedNCT02163681Not applicableResults posted
• Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)CompletedNCT02139306Phase 3Results posted
• A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic FibrosisCompletedNCT02137382Phase 3Results posted
• A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis SubjectsCompletedNCT02134353Phase 3Results posted
• Evaluating High Flow Humidification Therapy in Patients With Cystic FibrosisCompletedNCT02129803Not applicableResults posted
• Study of Ataluren (PTC124) in Cystic FibrosisTerminatedNCT02107859Phase 3Results posted
• Non Invasive Ventilation as Airway Clearance in Patients With Cystic FibrosisCompletedNCT02083263Not applicableResults posted
• Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label ExpansionCompletedNCT02070744Phase 2Results posted
• Blood Flow and Vascular Function in Cystic FibrosisCompletedNCT02057458Phase 2Results posted
• OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic FibrosisCompletedNCT02054156Phase 3Results posted
• Efficacy of TOBI Podhaler vs. Tobramycin Inhalation SolutionTerminatedNCT02038803Results posted
• Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis PatientsCompletedNCT02029521Not applicableResults posted
• IL-17 Neutrophils in CF Lung InflammationCompletedNCT02025829Results posted
• Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off CyclesTerminatedNCT02015663Phase 4Results posted
• Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic FibrosisCompletedNCT01983787Results posted
• Effect of Proton Pump Inhibitors on CF Pulmonary ExacerbationsCompletedNCT01983774Phase 2Results posted
• Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating MutationCompletedNCT01946412Phase 3Results posted
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisCompletedNCT01931839Phase 3Results posted
• Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR MutationCompletedNCT01897233Phase 3Results posted
• Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic FibrosisCompletedNCT01880723Not applicableResults posted
• Effect of Chronic Incretin-based Therapy in Cystic FibrosisCompletedNCT01879228Not applicableResults posted
• Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic FibrosisCompletedNCT01859390Phase 2Results posted
• Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)CompletedNCT01844778Phase 4Results posted
• Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis PatientsCompletedNCT01822197Not applicableResults posted
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807949Phase 3Results posted
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationCompletedNCT01807923Phase 3Results posted
• Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis PatientsCompletedNCT01784419Not applicableResults posted
• Cystic Fibrosis and Endothelial Function: At Rest and During ExerciseCompletedNCT01772758Phase 2Results posted
• Does a Daily Iron Tablet Improve Anemia in Cystic FibrosisCompletedNCT01755455Not applicableResults posted
• Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR MutationCompletedNCT01746784Phase 1Results posted
• Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis PatientsCompletedNCT01746095Phase 2Results posted
• A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic FibrosisCompletedNCT01712334Phase 4Results posted
• Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR MutationCompletedNCT01707290Phase 3Results posted

← Cystic Fibrosis overview